Trial intelligence / Profile preview

Phase 3 study of mometasone furoate/formoterol versus mometasone, formoterol, and placebo in persistent asthma

2006-001577-13Phase 3Completed

Sponsor
Merck & Co.
Start
Sep 2006
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
Countries
1
01

Overview

Phase 3, randomised trial of mometasone and formoterol in persistent asthma (4 arms), sponsored by Merck & Co. Primary endpoint: FEV1 AUC(0-12 hr) change from baseline to Week 12. Started Sep 2006; status: completed.

02

Drugs

mometasoneformoterol
03

Conditions

persistent asthma

Beyond the preview

Go deeper on 2006-001577-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-001577-13.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call